Paradoxical response during anti-tuberculosis treatment in immunocompetent patients;Respuesta paradójica durante el tratamiento tuberculostático en pacientes inmunocompetentes

Medicina Clinica

Volumn 133, Issue 16, 2009, Pages 637-643

  Fernández Fúnez, Ángel ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

Immunocompetent patients; Paradoxical response; Tuberculosis

Indexed keywords

GAMMA INTERFERON; HLA DR4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; HUMAN; IMMUNOPATHOGENESIS; LUNG; LYMPH NODE; PLEURA; PROGNOSIS; SHORT SURVEY; SKIN; TISSUE DISTRIBUTION; TREATMENT RESPONSE; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; IMMUNOCOMPETENCE; TUBERCULOSIS;

EID: 70350156944     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2008.12.020     Document Type: Short Survey

References (83)

1. Galbraith R.M., Eddleston A.L., Willians R., and Zackerman A.J. Fulminant hepatic failure in leukaemia and choriocarcinoma related in withdrawal of cytotoxic drug therapy. Lancet 2 (1975) 528-530
2. Powderly W.G., Landay A., and Lederman M.M. Recovery of the immune system with antiretroviral therapy. JAMA 280 (1988) 72-77
3. Chen J.W., and Johnson J.L. Paradoxical reaction in HIV and pulmonary TB. Chest 114 (1998) 933-936
4. Narita M., Ashkin D., Hollender E.S., and Pitchenik A.E. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 158 (1998) 157-161
5. Díez Ruiz-Navarro M. La tuberculosis en los albores del siglo xxi. Rev Esp Salud Publica 77 (2003) 183-187
6. Cheng V.C.C., Ho P.L., Lee R.A., Chan K.S., Chan K.K., Woo P.C.Y., et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV infected patients. Eur J Clin Microbiol Infect Dis 21 (2002) 803-809
7. Koch R. Weitre Mittheilunge uber ein Heilmittel gegen Tuberculosis. Disch Med Wochensch 16 (1890) 1029
8. Chloremis C.B., Padiatellis Z., Zou mbou lakis D., and Yannakos D. Transitory exacerbation of fever and roentgenographic findings during treatment of tuberculosis in children. Am Rev Tuberc 72 (1955) 526-536
9. Cheng V.C.C., Yam W.C., Woo P.C.Y., Lau S.K.P., Hung L.F.N., Wong S.P.Y., et al. Risk factors for development of paradoxical response during antituberculosis therapy in hiv-negative patients. Eur J Clin Microbiol Infect Dis 22 (2003) 597-602
10. Mert A., Bilir M., Ozturk R., Tabak F., Ozaras R., Tahan V., et al. Tuberculosis subcutaneous abscesses developing during military tuberculosis therapy. Scand J Infect Dis 32 (2000) 37-40
11. Wilkinson R.J., Hawkey C.R., and Davidson R.N. Reply to Garcia Vidal and Grau. Clin Infect Dis 41 (2005) 915-916
12. Mert A., and Ozaras R. Paradoxical reaction: can it be seen. After Completion of the anti-tuberculosis therapy?. Scand J Infect Dis 36 (2004) 78-79
13. Al Majad S.A. Study of paradoxical response to chemotherapy in tuberculous pleural effusion. Respir Med 90 (1996) 211-214
14. Campbell J.A., and Dyson A.J. Lymph node tuberculosis a comparison of various methods of treatment. Tubercle 58 (1977) 171-179
15. Teoh R., Humphries M.J., and O'Mahony G. Symptomatic intracranial tuberculoma developing during treatment of tuberculosis: a report of 10 patients and review of the literature. Q J Med 63 (1987) 449-460
16. Provencio-Pulla M., De la Fuente J., Hernaez J.M., Roman F., and Martínez López de Letona J. Intracranial tuberculoma: paradoxical expansion during medical treatment. Postgrad Med J 68 (1992) 487-488
17. Afghani B., and Lieberman J.M. Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. Clin Infect Dis 19 (1994) 1092-1099
18. Sinh H., Pandaya S.K., and Dastur D.K. Pathogenesis of unusual intracranial tuberculomas and tuberculous space-occupying lesion. J Neurosurg 29 (1968) 149-159
19. Hirsch C.S., Toossi Z., Othierno C., Johnson J.L., Luzze H., Ntambi L., et al. Depressed T cell interferon-gamma responses in pulmonary tuberculosis analysis of underlying mechanisms and modulation with therapy. J Infect Dis 180 (1999) 2069-2073
20. Hirsch C.S., Hussain R., Toosi Z., Dawood G., Shahaid F., and Ellner J.J. Cross-modulation by transforming growth factor beta in human tuberculosis: suppresion of antigen-driven blastogenesis and interferon gamma production. Proc Natl Acad Sci USA 93 (1996) 3193-3198
21. Hirsch C.S., Toossi Z., Johnson J.L., Luzze H., Ntambi L., Peters P., et al. Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. J Infect Dis 183 (2001) 779-788
22. Mustafa T., Bjune T.G., Jonson R., Pardo R.H., and Nilsen R. Increased expression of fax ligand in human tuberculosis and leprosy lesions: a potential novel mechanism in immune evasion in mycobacterial infection. Scan J Immunol 54 (2001) 630-639
23. Vanham G., Toossi Z., Hirsch C.S., Wallis R.S., Schwander S.K., Rich E.A., et al. Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/anergy. Tuber Lung Dis 78 (1997) 145-158
24. Youmans G.P. Mechanisms of immunity in tuberculosis. Pathobiol Annu 9 (1979) 131-137
25. Colover J. Acute demyelination in EAE alter pretreatment with foreing protein and muramyl dipeptide (MDP). En: Alvord EL, Kies MW, Suckling AT, editors. Experimental allergic encephalomyelitis a useful model for multiple sclerosis. New York: Alan R. Liss; 1984. p. 37-42.
26. Wilson C.D., Bohnsack J., and Weaver W.M. Effects of muramyl dipeptide on super-oxide anion and antimicrobial activity of human macrophages. Clin Exp Immunol 49 (1982) 371-376
27. Cheng S.L., Wang W.C., and Yang P.C. Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 11 (2007) 1290-1295
28. Reiser M., Fatkenheuer G., and Diehl V. Paradoxical expansion of intracranial tuberculomas during chemotherapy. J Infect 35 (1997) 88-90
29. Wallis R.S., Amir-Tahmasseb M., and Ellner J.J. Induction in interleukin 1 and tumour necrosis factor by mycobacterial proteins: the monocyte westerm blot. Proc Natl Acad Sci USA 87 (1990) 3348-3352
30. Cheng V.C., Yuen K.Y., Chan W.M., Wong S.S., Ma E.S., and Chan R.M. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 30 (2000) 882-892
31. Hawkey C.R., Yap T., Pereira J., Moore D.A., Davidson R.N., Pasvol G., et al. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis 40 (2005) 1368-1371
32. Dormans J., Burger M., Aguilar D., Hernández-Pando R., Kremer K., Rohol P., et al. Correlation of virulence, lung pathology, bacterial load and delayed type hypersensitivity responses after infection with different Mycobacterium tuberculosis genotypes in a BALB/c mouse model. Clin Exp Immunol 137 (2004) 460-468
33. Perrin F.M.R., Breen R.A.M., Lipman M.C.I., Shorten R.J., Gillespie S.H., and McHugh T.D. Is there a relation ship between Mycobacterium tuberculosis strain type and TB paradoxical reaction?. Thorax 60 (2005) 803-819
34. Wilkinson R.J., Llewelyn M., Toossi Z., Pasvol E., Lalvani A., Wright D., et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on susceptibility to tuberculosis amongst Gujarati Asians in west London: a case-control study. Lancet 355 (2000) 618-621
35. Cantorna M.T., Zhu Y., and Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 80 (2004) 1717S-1720S
36. Kumar R. Atypical response to chemotherapy in neurotuberculosis. Br J Neurosurg 12 (1998) 344-348
37. Chambers S.T., Hendrickse W.A., Record C., Rudge P., and Smith H. Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet 2 (1984) 181-183
38. Nicolls D.J., King M., Holland D., Bala J., and Del Rio C. Intracranial tuberculomas developing while on therapy for pulmonary tuberculosis. Lancet Infect Dis 5 (2005) 795-801
39. Mert A., Bilir M., Ozturk R., Tabak F., Ozaras R., Tahan V., et al. Tuberculous subcutaneous abscesses developing during miliary tuberculosis therapy. Scand J Infect Dis 32 (2000) 37-40
40. Berg J., Leonard A., Clancy C.J., and Nguyen M.H. Subcutaneous abscesses due to Mycobacterium tuberculosis: paradoxical expansion of disease during therapy for miliary tuberculosis. Clin Infect Dis 26 (1998) 231-232
41. Rietbroek R.C., Dahlmans R.P., Smedts F., Frantzen P.J., Koopman R.J., and Van der Meer J.W. Tuberculosis cutis miliaris disseminata as a manifestation of miliary tuberculosis: literature review and report of a case of recurrent skin lesions. Rev Infect Dis 13 (1991) 265-269
42. Chen C.H., Tsai J.J., Shih J.F., and Perng R.P. Tuberculous subcutaneous abscesses developing during chemotherapy for pulmonary tuberculosis. Scand J Infect Dis 25 (1993) 149-152
43. Price P., Keane N.M., Stone S.F., Cheong K.Y., and French M.A. MHC haplotypes affect the expression of opportunistic infections in HIV patients. Human Immunol 62 (2001) 157-164
44. Price P., Morahan G., Huang D., Stone E., Cheong K.Y.M., Castley A., et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 6 (2002) 2043-2047
45. Grange J.M., Kardijito T., and Setiabudi I. A study of acute-phase reactant proteins in Indonesian patients with pulmonary tuberculosis. Tubercle 65 (1984) 23-29
46. Kiblawi S.S.O., Jay S.J., Stonehill R.B., and Norton J. Fever response of patients on therapy for pulmonary tuberculosis. Am Rev Respir Dis 123 (1981) 20-24
47. Cheng V.C., Yuen K.Y., Wong S.S., Woo P.C.Y., Ho P.L., Lee R., et al. Immunorestitution diseases in patients not infected with HIV. Eur J Clin Microbiol Infect Dis 20 (2001) 402-406
48. Carvalho A.C.C., De Laco G., Saleri N., Pini A., Capone S., Manfrin M., et al. Paradoxical reaction during tuberculosis treatment in hiv-seronegativer patients. Clin Infect Dis 42 (2006) 894-895
49. Rao G.P., Nadh B.R., Hemaratnan A., Srinivas T.V., and Reddy P.K. Paradoxical progression of tuberculous lesions during chemotherapy of central nervous system tuberculosis. Report of four cases. J Neurosurg 83 (1995) 359-362
50. Orlovic D., and Smego R.A.J. Paradoxical tuberculous reactions in HIV-infected patients. Int J Tuberc Lung Dis 5 (2001) 370-375
51. Hejazi N., and Hassler W. Multiple intracranial tuberculomas with atypical response to tuberculostatic chemotherapy: literature review and a case report. Infection 25 (1997) 233-239
52. Loizou L.A., and Anderson M. Intracranial tuberculomas: correlations of computerized tomography with clinical-pathologycal findings. Q J Med 201 (1982) 104-114
53. Borah N.C., Maheshwari M.C., Mishra N.K., and Goulatia R.K. Appearance of tuberculoma during the course of TB meningitis. J Neurol 231 (1984) 269-270
54. De Angelis L.M. Intracranial tuberculoma: case report and review of the literature. Neurology 31 (1981) 1133-1136
55. Bagga A., Kaira V., and Ghai O.P. Intracranial tuberculoma: Evaluation and treatment. Clin Pediatr 27 (1988) 487-490
56. Mohanty A., Santosh V., Anandh B., Kulluri R., Vasuder M.K., Hegde T., et al. Diagnostic efficacy of sterotactic biopsies in intracranial tuberculomas. Surg Neurol 52 (1999) 252-257
57. Choi Y.W., Jeon S.C., Seo H.S., Park C.K., Hahm C.K., and Joo K.B. Tuberculous pleural effusion: new pulmonary lesions during treatment. Radiology 224 (2002) 493-502
58. Huseby J.S., and Hunddson L.D. Miliary tuberculosis and adult respiratory distress syndrome. Ann Intern Med 85 (1976) 609-611
59. Ellis M.E., and Webb A.K. Cause of death in-patients admitted to hospital for pulmonary tuberculosis. Lancet 1 (1983) 665-667
60. Hung S.C., and Chang S.C. New pulmonary lesions during therapy for extrapulmonary tuberculosis. Chest 116 (1999) 1794-1797
61. Chan H.S., and Pang J.A. Effect of corticosteroids on deterioration of endobronchial tuberculosis during chemotherapy. Chest 96 (1989) 1195-1196
62. Gupta R.C., Dixit R., Purohit S.D., and Saxena A. Development of pleural effusion in patients during anti-tuberculosis chemotherapy: analysis of twenty-nine cases with review of literature [abstract]. Indian J Chest Dis Allied Sci 42 (2000) 161-166
63. Cooke N.J., Crompton G.K., and Horne N.W. Unusual radiographic abnormalities observed during treatment of tuberculosis pleural effusion. Tubercle 55 (1974) 261-267
64. Stead W.W., Elzenholz A., and Stauss H.K. Operative and pathologic findings in twenty-four patients with syndrome of idiopathic pleurisy with effusion, presumably tuberculous. Am Rev Respir Dis 71 (1955) 473-502
65. Hiraoka K., Nagata N., Kawajiri T., Suzuki K., Kurokawa S., Kido M., et al. Paradoxical pleural response to antituberculous chemotherapy and isoniazid-induced lupus: review and report of two cases. Respiration 65 (1998) 152-155
66. British Thoracic Society Research Committee short course chemotherapy for tuberculosis of lymph nodes: a controlled trial. Br Med J. 1985;200:1106-8.
67. Lees A.W., and Munro J.B. Skin lesions and deafness in disseminated tuberculosis. Br Med J 1 (1954) 496-499
68. Kasahara K., Fukuoka A., Murakawa K., Okamura H., Mikasa K., Narita N., et al. Tuberculous peritonitis developing during chemotherapy for pulmonary and intestinal tuberculosis; a case report. Respirology 10 (2005) 257-260
69. Ohkouchi M., Inase N., Yasui M., and Miura H. Case of pubic tuberculous osteomyelitis and pericarditis during anti-tuberculosis chemotherapy [abstract]. Kekkaku 79 (2004) 531-535
70. Aubron C., L'Heriteau F., Laissy J.P., and Bouvet E. Paradoxical emergence of humerus osteomyelitis during treatment of pulmonary and lymph-node tuberculosis. Scand J Infect Dis 33 (2001) 79
71. Wendel K.A., Alwood K.S., Gachuhi R., Chaisson R.E., Bishai W.R., and Sterling T.R. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 120 (2001) 193-197
72. Desimone J.A., Pomerantz R.J., and Babinchak T.J. Inflammatory reactions in HIV-1-infected persons alter initiation of highly active antiretroviral therapy. Ann Intern Med 133 (2000) 447-454
73. Breen R.A.M., Smith C.J., Bettinson H., Dart S., Bannister B., Johnson M.A., et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 59 (2004) 704-707
74. Carter E.I., and Mates S. Sudden enlargement of a deep cervical lymph node during and after treatment for pulmonary tuberculosis. Chest 106 (1994) 1896-1898
75. Kumar R., Prakash M., and Jha S. Paradoxical response to chemotherapy in neurotuberculosis. Pediatr Neurosurg 42 (2006) 214-222
76. Onwubalili J.K., Scott G.M., and Smith H. Acute respiratory distress related to chemotherapy of advanced pulmonary tuberculosis: a study of tow cases and review of the literature. Q J Med 59 (1986) 599-610
77. García Vidal C., and Garau J. Systemic steroid treatment of paradoxical upgrading reaction in patients with lymph node tuberculosis. Clin Infect Dis 41 (2005) 915-916
78. Rodríguez Baño J., Muniain M.A., Aznar J., Pérez-Cano R., and Corral J.L. Systemic paradoxical response to antituberculous drugs resolution with corticosteroid therapy. Clin Microbiol Infect 3 (1997) 634-639
79. Fernández-Fúnez A., Gómez J., Alamillo A., and Sáez L. Polineuropatía desmielinizante como manifestación inicial de tuberculosis ganglionar y respuesta paradójica en una paciente sin inmunodepresión. Med Clin (Barc) 129 (2007) 77-78
80. Bukharie H. Paradoxical response to anti-tuberculosis drugs: resolution with corticosteroid therapy. Scand J Infect Dis 32 (2000) 96-97
81. Safdar A., Brown A.E., Kraus D.H., and Malkin M. Paradoxical reaction syndrome complicating aural infection due to Mycobacterium tuberculosis during therapy. Clin Infect Dis 30 (2000) 625-627
82. Ljungman P., Engelhard D., Link H., Biron P., Brandt L., Cordonnier C., et al. Treatment in interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 14 (1992) 831-835
83. Tsenova L., Sokol K., Freedman V.H., and Kaplan G. A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 177 (1998) 1563-1572